NCT04026997 - A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

December 17, 2020

Study Completion Date

December 17, 2020

Conditions

Gastroparesis

Interventions

DRUG

CIN-102 Dose 1

DRUG

CIN-102 Dose 2

DRUG

CIN-102 Dose 3

DRUG

Placebo

Trial Locations (19)

11023

Research Site 109, Great Neck

19140

Research Site 106, Philadelphia

27103

Research Site 120, Winston-Salem

29485

Research Site 119, Summerville

30322

Research Site 111, Atlanta

32224

Research Site 114, Jacksonville

33134

Research Site 117, Miami

33183

Research Site 118, Miami

38305

Research Site 107, Jackson

40202

Research Site 103, Louisville

57702

Research Site 115, Rapid City

66045

Research Site 110, Kansas City

68134

Research Site 121, Omaha

70072

Research Site 112, Marrero

71201

Research Site 104, Monroe

74104

Research Site 105, Tulsa

89123

Research Site 113, Las Vegas

91910

Research Site 101, Chula Vista

02215

Research Site 102, Boston